CN1261151C - Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method - Google Patents
Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method Download PDFInfo
- Publication number
- CN1261151C CN1261151C CN 02109347 CN02109347A CN1261151C CN 1261151 C CN1261151 C CN 1261151C CN 02109347 CN02109347 CN 02109347 CN 02109347 A CN02109347 A CN 02109347A CN 1261151 C CN1261151 C CN 1261151C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- cholecystitis
- chronic cholecystitis
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a medicine for treating acute and chronic cholecystitis and a preparation method thereof, wherein the medicine for treating acute and chronic cholecystitis is a Chinese patent medicine prepared from traditional Chinese medicines. At present, domestic medicines for treating acute and chronic cholecystitis prefer the function of relieving inflammation; gentamicin antibiotic medicines only can relieve the manifestations of diseases, the curative effect is unfavorable, the diseases relapse when withdrawal, long-term medicine administration is unfavorable to patients for maintaining the state of illness, and the patients can easily gain drug resistance. The medicine for treating acute and chronic cholecystitis is a Chinese materia medica preparation prepared from the following raw materials of the proportion by weight: bear gall powder, scutellaria root, bupleurum root, oriental wormwood, longhairy antenoron herb, curcuma root, szechwan chinaberry fruit and nutgrass galingale rhizome. The medicine for treating acute and chronic cholecystitis is used as a medicine for treating cholecystitis, which has the functions of relieving inflammation and fever, alleviating pain, inhibiting lithogenesis in vivo and reducing cholesterol, capillary permeability and cholecystitis complications.
Description
Technical field: the present invention relates to a kind of medicine for the treatment of acute and chronic cholecystitis.Be the Chinese patent medicine of feedstock production specifically, the invention still further relates to the preparation method of this medicine with Chinese medicine.
Background technology: acute and chronic cholecystitis is present commonly encountered diseases clinically, and morbidity in recent years has the trend that increases year by year.Its cardinal symptom is the frequent pain of right abdominal part, inappetence, bitter taste in the mouth and dry throat, and hyperpyrexia, jaundice appear in weight person, back part severe pain, and the patient is very painful, has a strong impact on the normal live and work of patient.
At present many gentamycin antibiotics class medicine can only be alleviated surface symptoms to the medicine of state's internal therapy primary disease based on simple antiinflammatory, and curative effect is undesirable, and drug withdrawal easily recurs, and the patient must not take medicine for a long time and keep, and is easy to generate Drug resistance.And the excision gallbladder is not suitable for older and is associated with the patient of other organ disease.So this disease of treatment by Chinese herbs of inventing a kind for the treatment of both the principal and secondary aspects of a disease has become the fervent expectation of extensive patients.
Summary of the invention: the object of the present invention is to provide a kind ofly to have antiinflammatory, analgesic, pain relieving, inhibition calculi in vivo and form, cholesterol reducing reduces capillary permeability, reduces cholecystitis medicine of cholecystitis complication effect and preparation method thereof
Above-mentioned purpose realizes by following technical scheme:
A kind of medicine for the treatment of acute and chronic cholecystitis, the Chinese medicine preparation that it is made by the following weight proportion raw material.
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
The medicine of the acute and chronic cholecystitis of described treatment, wherein the weight proportion of each raw material is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
The medicine of the acute and chronic cholecystitis of described treatment, said medicament are said dosage forms on any pharmaceutics.
The medicine of the acute and chronic cholecystitis of described treatment, said medicament are tablet, capsule, granule, oral liquid, injection.
The preparation method of the medicine of the acute and chronic cholecystitis of described treatment:
Get Radix Curcumae earlier, powder becomes fine powder; Radix Scutellariae drops into boiling water, decocts three times, is concentrated into relative density 1.05～1.08 (80 ℃), adds hydrochloric acid and transfers PH to 1～2, leaves standstill, and precipitation is dry, pulverizing is standby.Five kinds of Chinese medicine such as Herba Lysimachiae, Fructus Toosendan, Radix Bupleuri, Herba Artemisiae Scopariae, Rhizoma Cyperi decoct with water twice, being concentrated into relative density is the clear paste of 1.18～1.22 (80 ℃), adds ethanol and reaches 60% to containing the alcohol amount, filters, filtrate recycling ethanol is concentrated into the extractum of relative density 1.32～1.34 (60 ℃).Get Fel Ursi powder, Radix Curcumae fine powder, Radix Scutellariae extract and add in the above-mentioned extractum, mixing, cold drying, powder becomes fine powder, granulates, and makes tablet, capsule, granule, oral liquid, injection.
This technical scheme has following beneficial effect:
One, through Clinical Laboratory, this product obviously has antiinflammatory, analgesic, pain relieving, inhibition calculi in vivo and forms, and the effect of cholesterol reducing for reducing capillary permeability, reduces the cholecystitis complication and has significant effect.
Two, this product is a kind of Chinese medicine for the treatment of both the principal and secondary aspects of a disease, and long-term effect is good, and is evident in efficacy, and is difficult for recurrence after the drug withdrawal, and the patient does not take medicine for a long time at needs and keeps, and does not develop immunity to drugs.Avoided the misery of excision gallbladder, evoke complication cause other organ disease.
Three, medicine of the present invention has certain curative effect through the evidence safety non-toxic to acute and chronic cholecystitis, and its toxicology and pharmacodynamic experiment data are as follows:
1, give mouse stomach with Cmax and the maximum gastric capacity of irritating, per 8 hours once, every day three times, observes in the administration 24 hours and afterwards 7 days: tried mice and death and other abnormal response do not occur.It is 165.22g/kg/ day that experiment records the mice maximum tolerated dose, is 394.73 times of the clinical adult of this medicine consumption every day (, add up to crude drug 20.928g/kg body weight every day 3 times by each 4).The consumption per day that shows medicine of the present invention is safe.
2, long term toxicity test: respectively with 0.9g/kg, 4.5g/kg (symphysis medicine 4.13g/kg, 20.65g/kg) gives the administration of Wistar rat oral gavage, once a day, continuous irrigation stomach 60 days, result of the test shows that general state, behavioral activity and the diet situation and the matched group that are tried rat do not have significant difference; Hematology, liver function, renal function and organ coefficient and matched group more all do not have significant difference, show that it is safe taking medicine of the present invention for a long time.
3, to the influence of rabbit cholelithiasis due to the dihydrocholesterol
In feedstuff, sneak into dihydrocholesterol (1%), give around the continuous nursing of rabbit, every day while, gastric infusion was 1 time, matched group is given and cholagogic and lithagogue tablet, model control group is given and normal saline with volume, around the successive administration, measured the cholesterol level in serum and the bile in 24 hours after the last administration, result of the test sees Table 1.
The influence of rabbit cholelithiasis model serum and bile cholesterol due to the table 1 pair dihydrocholesterol
| Group | Dosage (g/kg) | Number of animals (only) | Chol content (mmol/l) in the serum (X ± SD) | Chol content (mmol/l) in the bile (X ± SD) | |
| Investigational agent | Heavy dose of group | 0.547 | 8 | 3.10±0.74 | 6.30±3.10 |
| Middle dosage group | 0.273 | 8 | 5.31±0.89 | 7.18±2.85 | |
| Small dose group | 0.137 | 8 | 6.04±1.01 | 9.41±3.05 | |
| Cholagogic and lithagogue tablet | 0.270 | 8 | 5.18±0.94 | 10.71±2.98 | |
| Normal saline | Same volume | 8 | 8.25±1.32 | 15.72±3.85 | |
The result shows: medicine of the present invention may obviously reduce the cholesterol level (P＜0.01) that raises in the rabbit anteserum and bile due to the dihydrocholesterol.
The influence of rabbit cholesterol calculus due to the table 2 pair dihydrocholesterol
| Group | Dosage (g/kg) | Number of animals (only) | Cholelithiasis incidence rate (%) | The P value | |
| Investigational agent | Heavy dose of group | 0.547 | 8 | 25.00 | ＜0.05 |
| Middle dosage group | 0.273 | 8 | 37.50 | ＞0.05 | |
| Small dose group | 0.137 | 8 | 62.50 | ＞0.05 | |
| Cholagogic and lithagogue tablet | 0.270 | 8 | 37.50 | ＞0.05 | |
| Normal saline | Same volume | 8 | 37.50 | ||
The result shows: medicine of the present invention is to the obvious suppression effect that is formed with of rabbit cholesterol calculus due to the dihydrocholesterol.
4, the influence of xylol induced mice inflammatory capillary permeability increase:
Get three variable concentrations of medicine of the present invention every days once to mouse stomach, successive administration three days, positive control drug are cholagogic and lithagogue tablet, chlorpheniramine maleate tablets, and the blank group is given the normal saline with volume, after the last administration 60 minutes, record after getting the organized processing that mice two ears symmetries area equates:
The influence that table 3 pair mice dimethylbenzene inflammatory capillary permeability increases
| Group | Dosage (g/kg) | Number of animals (only) | The OD value (X ± SD) | The P value | |
| Investigational agent | Heavy dose of group | 2.188 | 10 | 0.030±0.01 | ＜0.01 |
| Middle dosage group | 1.094 | 10 | 0.035±0.01 | ＜0.01 | |
| Small dose group | 0.547 | 10 | 0.050±0.02 | ＜0.01 | |
| Cholagogic and lithagogue tablet | 1.080 | 10 | 0.040±0.02 | ＜0.01 | |
| Chlorphenamine | 0.050 | 10 | 0.025±0.01 | ＜0.01 | |
| Normal saline | Same volume | 10 | 0.18±0.02 | ||
| Do not cause scorching normal mouse | 10 | 0.11±0.01 | ＜0.01 | ||
The result shows: medicine xylol inflammatory capillary permeability of the present invention increase has the antagonism (P＜0.01) of highly significant.
5, the influence of Dichlorodiphenyl Acetate induced mice Ovum Gallus domesticus album foot swelling
Get the large, medium and small dosage of trial drug, give rat oral gavage once every day, successive administration three days, after the last administration immediately feedwater load after 30 minutes in every the right back ankle subcutaneous injection of rat fresh egg white 0.1ml, measuring the ankle joint girth with tape respectively, is the swollen joint expansibility with the difference of left and right sides ankle joint girth.
The influence of foot swelling due to the table 4 pair rat Ovum Gallus domesticus album
| Group | Dosage (g/kg) | Number of animals (only) | Paw swelling (the mm of X ± SD) | |||||
| 0.5h | 1h | 2h | 4h | 6h | ||||
| Investigational agent | Heavy dose of group | 1.276 | 10 | 4.5±1.5 | 43±1.6 | 3.9±1.0 | 3.4±0.9 | 3.0±0.9 |
| Middle dosage group | 0.638 | 10 | 4.7±1.1 | 4.5±1.2 | 4.3±1.2 | 4.3±1.0 | 3.9±1.3 | |
| Small dose group | 0.319 | 10 | 4.7±1.2 | 4.8±1.0 | 4.8±1.3 | 4.5±1.3 | 4.0±1.5 | |
| Cholagogic and lithagogue tablet | 0.630 | 10 | 4.8±1.1 | 4.9±1.4 | 4.6±1.2 | 4.0±1.1 | 3.9±1.1 | |
| Dexamethasone | 0.030 | 10 | 4.2±1.1 | 4.0±1.3 | 3.8±1.2 | 3.0±0.6 | 2.3±0.8 | |
| Normal saline | Same volume | 10 | 6.3±1.4 | 6.4±1.2 | 6.0±1.8 | 5.6±1.4 | 5.0±1.2 | |
The result shows: foot swelling has the obvious suppression effect to medicine of the present invention to rat Ovum Gallus domesticus album.
6, the influence of Dichlorodiphenyl Acetate induced mice writhing response
Get large, medium and small three variable concentrations of medicine of the present invention, give the mouse stomach administration respectively, once a day, successive administration three days, 1 hour every mouse peritoneal is injected 0.7% acetic acid after the last administration, mouse writhing number of times in 20 minutes behind the record injection acetic acid.
The influence of table 5 Dichlorodiphenyl Acetate induced mice writhing response
| Group | Dosage (g/kg) | Number of animals (only) | Annotate and to turn round body number (inferior) (X ± SD) behind the acetic acid in the 20min | The P value | |
| Investigational agent | Heavy dose of group | 2.188 | 10 | 17.23±10.92 | ＜0.01 |
| Middle dosage group | 1.094 | 10 | 20.13±13.41 | ＜0.01 | |
| Small dose group | 0.547 | 10 | 26.74±16.58 | ＜0.05 | |
| Cholagogic and lithagogue tablet | 1.080 | 10 | 25.17±13.94 | ＜0.01 | |
| Rotundine | 0.060 | 10 | 13.18±10.92 | ＜0.01 | |
| Normal saline | Same volume | 10 | 49.56±21.23 | ||
The result shows: the writhing response of medicine Dichlorodiphenyl Acetate induced mice of the present invention has significant antagonism (P＜0.01).
The main pharmacodynamics result of study shows: medicine of the present invention has the cholelithiasis of inhibition and forms antiinflammatory, analgesic activity.
Embodiment 1:
A kind of medicine for the treatment of acute and chronic cholecystitis is characterized in that the Chinese medicine preparation that it is made by the following weight proportion raw material.
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
Embodiment 2:
The medicine of the acute and chronic cholecystitis of embodiment 1 described treatment, wherein the weight proportion of each raw material is with kilogram:
Fel Ursi powder 2 or 10 or 15, Radix Scutellariae 30 or 40 or 50 or 60, Radix Bupleuri 30 or 40 or 50, Herba Artemisiae Scopariae 55 or 60 or 65, Herba Lysimachiae 50 or 55 or 60 or 65 Radix Curcumaes 5 or 10 or 15 or 20, Fructus Toosendan 5 or 10 or 15 or 20, Rhizoma Cyperi 35 or 40 or 45 or 50.
Embodiment 3:
The medicine of the above-mentioned acute and chronic cholecystitis of treatment, wherein the weight proportion of each raw material is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Better effects if during Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
The medicine of the above-mentioned acute and chronic cholecystitis of treatment, said medicament are said dosage forms on any pharmaceutics, comprise tablet, capsule, granule, oral liquid, injection or the like.
Embodiment 4:
Medicine of the present invention is to make (consumption is a weight portion) by following component:
Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50
Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20
Fructus Toosendan 5～20 Rhizoma Cyperis 35～50
The optimum weight of medicine of the present invention (part) proportioning is:
Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5
Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5
Above-mentioned each component is made medicine production method of the present invention is:
1. turmeric powder is become fine powder;
2. Radix Scutellariae drops in the boiling water and decocts, and medicinal residues discard, and extracting solution is concentrated into the clear paste shape, and adding hydrochloric acid is transferred pH value to 1～2, leaves standstill, and filters, and precipitation is dry, pulverizing is standby;
3. Herba Lysimachiae, Fructus Toosendan, Herba Artemisiae Scopariae, Radix Bupleuri, Rhizoma Cyperi five kinds of Chinese medicine extracting in water, medicinal residues discard, and extracting solution is concentrated into the clear paste shape, adds ethanol and reaches 60% to containing the alcohol amount, filters, and filtrate recycling ethanol also is concentrated into the extractum that relative density is 1.33～1.34 (60 ℃);
4. Fel Ursi powder, Radix Curcumae fine powder, Radix Scutellariae extract add in the above-mentioned clear paste, mixing, and drying, powder becomes fine powder, adds suitable adjuvant, makes corresponding granule, tablet, capsule, or further makes oral liquid, injection.
Usage and consumption: oral, one time 4,3 times on the one.
Claims (4)
- One kind the treatment acute and chronic cholecystitis medicine, it is characterized in that the Chinese medicine preparation that it is made by the following weight proportion raw material:Fel Ursi powder 2～15 Radix Scutellariaes 30～60 Radix Bupleuri 30～50Herba Artemisiae Scopariae 55～65 Herba Lysimachiaes 50～65 Radix Curcumaes 5～20Fructus Toosendan 5～20 Rhizoma Cyperis 35～50.
- 2. the medicine of the acute and chronic cholecystitis of treatment according to claim 1 is characterized in that, wherein the weight proportion of each raw material is:Fel Ursi powder 5 Radix Scutellariaes 50 Radix Bupleuri 41.5 Herba Artemisiae Scopariaes 62.5Herba Lysimachiae 62.5 Radix Curcumaes 10 Fructus Toosendans 10 Rhizoma Cyperis 41.5.
- 3. the medicine of the acute and chronic cholecystitis of treatment according to claim 1 and 2 is characterized in that said medicine is tablet or capsule or granule or oral liquid or injection.
- 4. the preparation method of the medicine of claim 1 or the acute and chronic cholecystitis of 2 or 3 described treatments is characterized in that:Get Radix Curcumae earlier, powder becomes fine powder; Radix Scutellariae drops into boiling water, decoct three times, be concentrated into relative density 1.05～1.08 in the time of 80 ℃, add hydrochloric acid and transfer PH to 1～2, leave standstill, precipitation is dry, pulverize standby, Herba Lysimachiae, Fructus Toosendan, Radix Bupleuri, Herba Artemisiae Scopariae, five kinds of Chinese medicine such as Rhizoma Cyperi decoct with water twice, be concentrated in the time of 80 ℃ relative density and be 1.18～1.22 clear paste, add ethanol and reach 60%, filter to containing the alcohol amount, filtrate recycling ethanol, be concentrated into the extractum of relative density 1.32～1.34 in the time of 60 ℃, get Fel Ursi powder, the Radix Curcumae fine powder, Radix Scutellariae extract adds in the above-mentioned extractum, mixing, cold drying, powder becomes fine powder, granulates, and makes tablet or capsule or granule or oral liquid or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109347 CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02109347 CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1446554A CN1446554A (en) | 2003-10-08 |
| CN1261151C true CN1261151C (en) | 2006-06-28 |
Family
ID=28048524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02109347 Expired - Lifetime CN1261151C (en) | 2002-03-24 | 2002-03-24 | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1261151C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101045116B (en) * | 2007-04-18 | 2010-05-26 | 孙晓波 | Traditional Chinese medicine for treating cholecystitis |
| CN102872270B (en) * | 2012-09-25 | 2013-12-18 | 朱风文 | Traditional Chinese medicine for treating chronic cholecystitis |
| CN104771697A (en) * | 2015-04-14 | 2015-07-15 | 青岛辰达生物科技有限公司 | Pharacetuical composition for treating cholecystitis |
| CN104958706A (en) * | 2015-07-21 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicine composition for treating chronic cholecystitis |
-
2002
- 2002-03-24 CN CN 02109347 patent/CN1261151C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1446554A (en) | 2003-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940695B (en) | Medicine composition for treating gout | |
| CN1814215A (en) | Medicine for treating gout and gout arthritis | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
| CN1261151C (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN102631415B (en) | Traditional Chinese medicine composite as well as product and application thereof | |
| CN100335083C (en) | Pile treating Chinese medicine prepn and its production process | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN102441064A (en) | Traditional Chinese medicine composition for treating diabetes and preparation thereof | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN1954877A (en) | Chinese medicinal composite for treating ischemic necrosis of femoral head and its preparation method | |
| CN1899439A (en) | Chinese medicine composition for treating goat and its use | |
| CN104027450B (en) | A kind of Chinese medicine composition for the treatment of diabetes | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN103405745A (en) | Traditional Chinese medicine composition for treating canine gastroenteritis | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| CN101926955B (en) | Medicament for treating stomach illness | |
| CN102133274A (en) | Chinese medicinal composition | |
| CN100998781B (en) | Traditional Chinese medicine capsule for relieving exterior syndrome, removing dampness regulating the stomach and its preparing method | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN101607061A (en) | A kind of drug regimen of protecting gastric mucosa and preparation method thereof | |
| CN1814250A (en) | Chinese medicine composition for treating liver cirrhosis ascites and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060628 |
|
| RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20100901 |